Select a community
MS
Find out more about the PatientsLikeMe
MS Community
Home > Community Treatment Reports > Medrol DosePak (methylprednisolone) Treatment Report
What is Medrol DosePak?

MedrolĀ® Dosepakā„¢ is a brand name for methylprednisolone primarily used as an anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases including those of hematologic, allergic, inflammatory, neoplastic, and autoimmune origin.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Other 7 0
Support another treatment 4 0
Slow my MS progress 3 0
Pain 2 0
Exacerbation (relapse) MS 2 0
Heavy sensation in legs 1 0

Mouse over the table for more information

Dosages

  20mg as needed 4 mg all the time (24/7) 4mg as needed 4 mg daily 8 mg daily 12 mg daily 20 mg daily 50 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 3 Number of Patients: 3 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Medrol DosePak (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended
12 86% Course of treatment ended: 86%
Did not seem to work
1 7% Did not seem to work: 7%

See all 13 patients who’ve stopped taking Medrol DosePak

Currently Taking Medrol DosePak

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
2
2
1
0
0

Stopped Taking Medrol DosePak

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
11
0
1
0
1
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
0 0%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
0 0%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 22, 2009.